Stoke Therapeutics, Inc.'s Board of Directors approved a discretionary bonus of $697,125 for Chief Executive Officer Ian F. Smith on February 13, 2026. Mr. Smith did not participate in the Company's 2025 annual bonus program. The determination to grant the bonus was based upon the Company's clinical and financial performance during the period following his appointment as interim CEO in March 2025 and permanent CEO in October 2025. The bonus amount represents the full target annual bonus Mr. Smith would have received had he participated in the 2025 annual bonus program. Corporate goal achievement for the Company under the 2025 annual bonus program was determined by the Board to be 150% of target.